Gene Therapy to Target BCMA and CD38 for Relapsed and RefractoryMultiple Myeloma is under clinical development by ICell Gene Therapeutics and currently in Phase I for Refractory Multiple Myeloma. According to GlobalData, Phase I drugs for Refractory Multiple Myeloma have a 78% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Gene Therapy to Target BCMA and CD38 for Relapsed and RefractoryMultiple Myeloma’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Gene Therapy to Target BCMA and CD38 for Relapsed and RefractoryMultiple Myeloma overview
Gene therapy is under development for the treatment of relapsed and refractory multiple myeloma. The therapeutic candidate constitutes lentiviral transfected chimeric antigen receptor (CAR) engineered T cells expressing BCMA scFV antibody domain and CS1 scFV antibody domain. It acts by targeting BCMA and CD38. The therapeutic candidate is developed based on CAR-T technology. It is administered through intravenous route.
See Also:
ICell Gene Therapeutics overview
iCell Gene Therapeutics (ICell Gene) is a biotechnology company. The company research and develops chimeric antigen receptor engineered cells that target multiple types of cancer with poor prognoses. It offers CARvac, T-cell targeted, compound CAR’s and universal CAR’s. ICell Gene offers orphan drug designation for five CARs in multiple myeloma, peripheral t-cell lymphoma, acute myeloid leukemia, b-acute lymphocytic leukemia and t-cell acute lymphocytic leukemia. The company creates novel CAR constructs and CAR enhancing technologies for applicability of transduced T and NK cells. It has operations in the US and China. ICell Gene is headquartered in Brookhaven, New York, the US.
For a complete picture of Gene Therapy to Target BCMA and CD38 for Relapsed and RefractoryMultiple Myeloma’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
